Loading clinical trials...
Loading clinical trials...
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will b...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more
NCT07164170 · Non-Small Cell Lung Cancer
NCT05211895 · Non-Small Cell Lung Cancer
NCT07267000 · Non-Small Cell Lung Cancer, Exercise Training, and more
NCT07489066 · Carcinoma, Non-Small-Cell Lung, and more
Northwest Alabama Cancer Center
Muscle Shoals, Alabama
Agajanian Institute of Oncology and Hematology
Montebello, California
Bridgeport Hospital
Bridgeport, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions